La Cañada Flintridge, CA, United States of America

Pamela J Bjorkman

This inventor holds 33 USPTO granted patents and 16 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in HIV Antibodies. Top assignees: California Institute of Technology, The Rockefeller University, Bio-Rad Laboratories, Inc.. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pamela J Bjorkman. Retrieved from https://idiyas.com/inventor/pamela-j-bjorkman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 33 (Patent Applications = 16)

% Patents Active = 87.9

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 147(Granted Patents)

Location History:

La Canada, CA (US) (2016 - 2021)
Pasadena, CA (US) (1997 - 2022)
La Canada Flintridge, CA (US) (2017 - 2023)
Altadena, CA (US) (2023 - 2024)

Company Filing History:

29 out of 4,632

California Institute of Technology

patents

25 out of 751

The Rockefeller University

patents

5 out of 1,072

Bio-Rad Laboratories, Inc.

patents

4. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

HIV Antibodies

Vaccine Immunogens

Neutralizing Antibodies

Polyreactivity

CD4 Binding Site

HIV Escape Mutants

Glycan-Dependent Variants

HAADS

Epitope Binding

HFE Protein

Iron Overload Treatment

Antibody Variants

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12534515 - BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODIES AND METHODS OF USE THEREOF (2026-01-27),

2. 12459990 - Anti-HIV vaccine antibodies with reduced polyreactivity (2025-11-04),

3. 12440553 - Multivalent carriers and related vaccine compositions (2025-10-14),

4. 12428472 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof (2025-09-30),

5. 12338277 - Broadly neutralizing antibodies that target HIV ENV V3 N-glycans (2025-06-24),

6. 12239698 - HIV vaccine immunogens (2025-03-04),

7. 12173052 - HIV-1 gp120 CD4 binding site antibodies targeting HIV escape mutants (2024-12-24),

8. 12071470 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof (2024-08-27),

9. 12054538 - Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120 (2024-08-06),

10. 11897940 - Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof (2024-02-13),

11. 11649276 - Broadly-neutralizing anti-HIV antibodies (2023-05-16),

12. 11634478 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof (2023-04-25),

13. 11472868 - Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120 (2022-10-18),

14. 11325966 - Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof (2022-05-10),

15. 11155605 - Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits (2021-10-26),

Title: The Innovative Journey of Inventor Pamela J Bjorkman

Introduction: Pamela J Bjorkman, a pioneering inventor based in La Canada Flintridge, CA (US), has made significant contributions to the field of innovation with her groundbreaking work.

Latest Patents: Pamela J Bjorkman's latest patents focus on advancements in biotechnology, particularly in the development of novel therapeutic molecules for treating infectious diseases.

Career Highlights: With a distinguished career spanning over two decades, Pamela J Bjorkman has established herself as a leading figure in the world of inventors. Her work has been instrumental in shaping the landscape of modern biotechnology.

Collaborations: Throughout her career, Pamela J Bjorkman has collaborated with top research institutions, universities, and biotech companies to further her research and bring her innovative ideas to life. Her collaborative spirit has led to groundbreaking discoveries in the field.

Conclusion: Pamela J Bjorkman's relentless pursuit of innovation and her dedication to pushing the boundaries of biotechnology have solidified her position as a trailblazing inventor. Her work continues to inspire future generations of inventors to think outside the box and strive for excellence in their pursuits.

Profile summary based on public USPTO records.